Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumor × alectinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 21 Neoplasms 5 Lung Neoplasms 4 Neoplasm Metastasis 3 Hematologic Neoplasms 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Solid Tumors 1 Sarcoma 1 Rare Tumour 1 Rare Tumor 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Multiple Endocrine Neoplasia Type 2a 1 Lymphoproliferative Disorders 1 Lymphoma, Large-Cell, Anaplastic 1 Lung Diseases 1 Glioblastoma 1 Genomic Instability 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Hepatocellular 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1 Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡